Labcorp Q4 Earnings: Revenue And EPS Beat, Expects Strong 2025 Growth, Analyst Reiterates Outperform On Stable 2025 Outlook

Core Insights - Laboratory Corp reported fourth-quarter 2024 adjusted earnings per share of $3.45, an increase from$ 3.30 a year ago, surpassing the consensus estimate of $3.39 [1] - Sales rose 9.8% year-over-year to$ 3.33 billion, nearly matching the consensus of $3.31 billion, driven by organic revenue growth of 5.4%, acquisitions net of divestitures of 4%, and foreign currency translation of 0.3% [1] - Adjusted operating income for the quarter was$ 423.2 million, or 12.7% of revenue, compared to $394.9 million, or 13%, in the same quarter last year [2] Company Performance - The company experienced exceptional results in 2024, attributed to both organic and inorganic growth, with a focus on high-growth areas such as oncology, women's health, neurology, and autoimmune disease [2] - The diagnostics segment is benefiting from favorable macro tailwinds, while the Biopharma Laboratory Services segment is seeing solid growth in central labs [3] Future Guidance - LabCorp expects adjusted EPS for 2025 to be between$ 15.60 and $16.40, compared to the consensus of$ 16.0, and anticipates sales of $13.9 billion to$ 14.1 billion against a consensus of $13.8 billion [4] - The guidance includes expected sales growth of 6.5% to 7.7% for Diagnostics Laboratories and 3.0% to 5.0% for Biopharma Laboratory Services in 2025 [4] Market Reaction - Laboratory Corp's stock was down 0.92% at$ 247.68 during the last check on Thursday [4]